Effect of Food on the Pharmacokinetics of Olaparib after Oral Dosing of the Capsule Formulation in Patients with Advanced Solid Tumors
作者: Christian RolfoHelen SwaislandKarin LeunenAnnemie RuttenPatricia SoetekouwSarah SlaterHenk M. W. VerheulAnitra FieldingKaren SoWendy BannisterEmma Dean
作者单位: 1University Hospital Antwerp
2Therakin Consulting
3University Hospitals Leuven
4Translational Cancer Research Group Antwerp
5Maastricht University Medical Center
6Cancer Research UK
7VU University Medical Center
8AstraZeneca
9PHASTAR
10The Christie NHS Foundation Trust
刊名: Advances in Therapy, 2015, Vol.32 (6), pp.510-522
来源数据库: Springer Journal
DOI: 10.1007/s12325-015-0214-4
关键词: Food effectOlaparibOlaparib capsulePARP inhibitionPharmacokineticsPKPoly(ADP-ribose) polymerase (PARP) inhibitor
英文摘要: Abstract(#br) Background(#br)The oral, potent poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib, is well tolerated at doses of ≤400 mg twice daily (BID) (administered as capsules), and has shown efficacy in patients with advanced BRCA -mutated ovarian and breast cancer.(#br) Methods(#br)This Phase I, open-label, randomized trial investigates the effect of food on the pharmacokinetics of olaparib in patients with refractory/resistant advanced solid tumors. In Part A, a three-period crossover study, patients received a single oral dose of olaparib 400 mg (8 × 50 mg capsules) in three prandial states: fasted, a high-fat meal or a standard meal (with a 5–14 day washout). Blood samples for pharmacokinetic (PK) assessments were taken pre-dose and up to 72 h post-dose. After completing Part...
全文获取路径: PDF下载  Springer  (合作)
分享到:
来源刊物:
影响因子:2.125 (2012)

×
关键词翻译
关键词翻译
  • after 在之后